Johannesburg, South Africa — The World Health Organization (WHO) has initiated a pivotal clinical trial for two potential treatments against the Ebola outbreak in the Democratic Republic of the Congo (DRC). This marks the first patient enrollment in the trial, which is designed to evaluate the safety and efficacy of the treatments against the Bundibugyo strain of Ebola, a rare species with no approved treatment or vaccine.
The trial, coordinated by DRC’s National Institute for Biomedical Research, is supported by a coalition including WHO and conducted in close cooperation with the affected communities. WHO Director-General Tedros Adhanom Ghebreyesus emphasized the comprehensive supportive care and close follow-up provided to patients enrolled in the trial, highlighting the importance of community engagement in ensuring access to therapeutics if the treatments are proven safe and effective.
The treatments under evaluation are monoclonal antibody MBP134 and the antiviral drug remdesivir, with studies planned on their use alone and in combination.
The trial is a collaborative effort involving key partners, including ALIMA, Oxford University, and the WHO, aiming to contribute to broader efforts to contain the spread of the disease.
The Bundibugyo strain of Ebola has posed particular challenges due to its rarity and the absence of existing treatments, making the trial’s focus on this strain particularly crucial.
As the trial progresses, it is anticipated to yield valuable data on the effectiveness of the treatments being tested, potentially paving the way for more effective treatments against Ebola in the future.
*Additional reporting by ImNews | Sources consulted: 5*
—
This original article was produced by the ImNews editorial team
Source: enca
Source: Siya Tsewu
